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SUMMARY
Prosenescence therapy has recently emerged as a
novel therapeutic approach for treating cancer.
However, this concept is challenged by conflicting
evidence showing that the senescence-associated
secretory phenotype (SASP) of senescent tumor
cells can have pro- aswell as antitumorigenic effects.
Herein, we report that, inPten-null senescent tumors,
activation of the Jak2/Stat3 pathway establishes an
immunosuppressive tumor microenvironment that
contributes to tumor growth and chemoresistance.
Activation of the Jak2/Stat3 pathway in Pten-null
tumors is sustained by the downregulation of
the protein tyrosine phosphatase PTPN11/SHP2,
providing evidence for the existence of a novel
PTEN/SHP2 axis. Importantly, treatment with doce-
taxel in combination with a JAK2 inhibitor repro-
grams the SASP and improves the efficacy of
docetaxel-induced senescence by triggering a
strong antitumor immune response in Pten-null
tumors. Altogether, these data demonstrate that
immune surveillance of senescent tumor cells can
be suppressed in specific genetic backgrounds but
also evoked by pharmacological treatments.
INTRODUCTION
Cellular senescence, an irreversible cell growth arrest involving
the p53 and the p16INKA tumor suppressors, can be triggered
by different insults including activation of oncogenes (onco-
gene-induced senescence [OIS]) or loss of tumor-suppressor
genes (Braig et al., 2005; Chen et al., 2005; Collado, 2010).
Over the past years, several in vivo evidences have demon-
strated that senescence opposes tumor initiation and progres-
sion in different mouse models (Collado, 2010; Nardella et al.,
2011). However, recent findings demonstrate that senescent
tumor cells secrete a variety of immune modulators and inflam-
matory cytokines, referred to as the senescence-associated
secretory phenotype (SASP), that mediate opposing and contra-
dictory effects. The SASP can stimulate the innate and adaptive
antitumor immune response (a process designated as ‘‘senes-
cence surveillance’’), leading to tumor clearance, but also pro-
motes tumorigenesis by supporting the proliferation of neigh-
boring tumor cells (Kang et al., 2011; Xue et al., 2007; Coppe´
et al., 2010; Rodier and Campisi, 2011; Davalos et al., 2010).
Of note, the SASP can also hinder chemotherapy efficacy (Jack-
son et al., 2012). Therefore, the contradictory effects of the SASP
cast doubts over the possibility to use treatments that enhance
senescence for cancer therapy (Collado, 2010; Nardella et al.,
2011). Moreover, whereas cytokines released by senescent tu-
mors have been shown to positively regulate the antitumor im-
mune response in some experimental models, it is unknown
whether cytokines released by senescent tumors may also favor
an immunosuppressive tumor microenvironment. An intriguing
possibility is that the genetic background of senescent tumor
cells may dictate the strength and composition of the cytokines
released by the tumor, therefore impacting differently on the
tumor microenvironment, specifically the immune system. We
have previously demonstrated that Pten-loss-induced cellular
senescence (PICS) is a novel type of cellular senescence
response that occurs in vivo and that can be enhanced by phar-
macological treatments (Alimonti et al., 2010). Pten-null prostate
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conditional mice (Ptenpc/) develop a prostatic intraepithelial
neoplasia (PIN) characterized by a strong senescence response
that progresses to invasive adenocarcinoma. This suggests that
the SASP of Ptenpc/ tumors may drive protumorigenic rather
than antitumorigenic effects. Thus, the concomitant presence
of a senescent component and a proliferative compartment
within the same tumor, along with a previously uncharacterized
SASP and tumor immune response, makes Ptenpc/ mice a
suitable mouse model to study the composition of the SASP
and develop treatments that reprogram the protumorigenic ef-
fects of the senescence secretome.
RESULTS
Pten-Null Senescent Tumors Are Characterized by an
Immunosuppressive Tumor Microenvironment
Starting from 7weeks of age, Ptenpc/mice develop PIN, a pre-
malignant prostatic lesion characterized by a strong senescence
response, as indicated by the senescence-associated b-galac-
tosidase (SA-b-gal) positivity; fluorescein di-b-D-galactopyrano-
side staining; and increased expression of p16, p21, and
plasminogen activator inhibitor-1 (Figures 1A, left, and S1A;
Collado and Serrano, 2006). To characterize the cytokine profile
of Ptenpc/ senescent tumors, we usedmagnetic-activated cell
sorting (MACS) to isolate and separate prostate epithelial cells
from both stromal and immune cells (Figure 1A, right). The
efficiency of purification was controlled by fluorescence-acti-
vated cell sorting (FACS) analysis (Figure S1B). Purified
Ptenpc/ epithelial cells were lysed and protein extracts loaded
in a cytokine protein array to allow high-throughput multianalyte
profiling of 40 different cytokines. Interestingly, the SASP of PICS
was characterized by increased levels of several cytokines re-
ported to play a negative role in cancer by favoring an im-
mune-suppressive tumor microenvironment (Vanneman and
Dranoff, 2012; Acharyya et al., 2012; Ostrand-Rosenberg and
Sinha, 2009; Figures 1B, left, and S1C). However, potent
chemoattractant cytokines that have been previously shown
to play a role in the process of inflammation associated to
senescence surveillance in OIS (Xue et al., 2007) were also upre-
gulated in Ptenpc/ senescent tumors (Figures 1B, right, and
S1C). In line with the cytokine array profile, FACS analysis
showed that Ptenpc/ tumors were strongly infiltrated by
CD11b+Gr-1+ myeloid cells, in absence of CD4+, CD8+, and nat-
ural killer (NK) infiltrates (Figures 1C and S1D). CD11b+Gr-1+
myeloid cells were granulocytic myeloid-derived suppressor
cells (MDSCs) (Figure S1E), an immune-suppressive subset
that blocks both proliferation and activity of CD4+, CD8+, and
NK cells (Gabrilovich andNagaraj, 2009). To assess the suppres-
sive activity of CD11b+Gr1+ cells in vivo, we sorted these cells
directly from the Ptenpc/ tumors and cocultured them with
CD8+ T cells. Notably, tumor-infiltrating CD11b+Gr1+ cells sup-
pressed the proliferation of CD8+ T cells (Figure 1D). Presence
of MDSCs explained why CD8+ T and NK cells recovered from
Ptenpc/ tumors were not cytotoxic (Figure S1F and S1G).
Recent evidence in a different mouse model indicates that
senescent tumor cells are cleared by the immune system, a
process termed senescence surveillance. Impairment of this
response results in the development of aggressive tumors
because the remaining senescent cells support tumorigenesis
by secreting a variety of cytokines that favor the growth of non-
senescent tumor cells (Xue et al., 2007; Kang et al., 2011). We
then speculated that the immunosuppressive tumor microenvi-
ronment of Ptenpc/ tumors could impair senescence surveil-
lance sustaining tumor progression. We therefore monitored
the number of senescent cells in Ptenpc/ tumors at different
times (from 7 to 15 weeks of age; Trotman et al., 2003). Interest-
ingly, the percentage of senescent cells in Ptenpc/ tumors re-
mained constant over time (Figure 1E), in contrast with previous
findings in OIS (Kang et al., 2011). These data suggest that, in
Ptenpc/ tumors, the adaptive immunity could be impaired, ex-
plaining why senescent tumor cells were not removed. To vali-
date this hypothesis, we generated the Ptenpc/; Rag1/
mouse model to induce PICS in a genetic background that lacks
adaptive immunity (Figure S1H;Mombaerts et al., 1992). Consis-
tent with our hypothesis, Ptenpc/; Rag1/ mice developed
prostate tumors with size and histology comparable to
Ptenpc/ mice (Figure 1F; Kang et al., 2011). More importantly,
the percentage of p16 and pHP1g-positive cells and SA-b-gal
staining between Ptenpc/ and Ptenpc/; Rag1/ tumors re-
mained comparable over time (Figures 1E and 1F). Altogether,
these data indicate that senescent cells are not removed by
the adaptive immunity in Ptenpc/ tumors, in contrast with pre-
vious findings in OIS (Kang et al., 2011). Therefore, the lasting se-
nescent cells in these tumorsmay become a source of mitogenic
cytokines that promote tumor progression.
The Jak2/Stat3 Pathway Is Activated in Ptenpc/
Senescent Tumors
The SASP of PICS pointed to Stat3 as a putative orchestrator of
this immunosuppressive cytokine network (Yu et al., 2009).
Indeed, several cytokines secreted by Ptenpc/ tumors such
as (C-X-C motif) ligand 1 (CXCL1), CXCL2, interleukin-6 (IL-6),
and IL-10 are transcriptionally regulated by Stat3. Therefore,
we checked the status of Stat3 phosphorylation in Ptenpc/
Figure 1. Immunosuppressive Microenvironment in PICS
(A) p16 IHC and b-galactosidase staining in Ptenpc+/+ and Ptenpc/ mice (left). Experimental setup (right).
(B) Cytokine protein profile of purified prostatic epithelial cells isolated from prostates of 8-week-old Ptenpc+/+ and Ptenpc/ mice (n = 3; *p < 0.05; **p < 0.01;
***p < 0.001).
(C) FACS analysis of tumor-infiltrating CD11b+Gr1+ immune cells in Ptenpc/ tumors (n = 7; ***p < 0.001).
(D) Scheme (left) and quantification (right) of the CD8+ suppression assay (see also Experimental Procedures). Immune-suppressive spleenic Treg was used as a
positive control. (n = 3 to 4; *p < 0.05; **p < 0.01).
(E) Quantification of p16 and pHP1g-positive cells in Ptenpc/ and Ptenpc/; Rag1/ tumors at different time points. Insets are representative images from p16
IHC and pHP1g IF staining (CK18 = cytokeratin 18 in gray).
(F) Gross anatomy (top), hematoxylin and eosin (H&E), b-galactosidase staining (bottom), and relative tumor volume (right) of anterior prostates (APs) in Ptenpc/
and Ptenpc/; Rag1/ mice at 15 weeks of age (n = 4). Data are represented as mean ± SEM.
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tumors. Western blot analysis, immunohistochemistry (IHC)
staining, and immunofluorescence (IF) confocal imaging re-
vealed that Stat3 was strongly phosphorylated on tyrosine 705
(Y705) in Ptenpc/ tumors when compared with normal pros-
tates (Figures 2A–2D, S2A, and S2B). Note that Ptenpc+/
mice, which develop nonsenescent PIN lesions at 5 months of
age (Alimonti et al., 2010; Trotman et al., 2003), stained
completely negative for pStat3 (Figures S2A and S2B). Phos-
phorylation of Stat3 in Ptenpc/ tumors was also associated
with the increased phosphorylation (five times more than in
normal prostate) of the nonreceptor Janus kinase 2 (Jak2) (Fig-
ure 2A), an upstream activator of Stat3 (Parganas et al., 1998).
Interestingly, IF analysis on consecutive sections from Ptenpc/
tumors revealed that, at the onset of senescence (8–10 weeks),
the majority of the pStat3-positive epithelial cells stained nega-
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Figure 2. Stat3 Is Activated in Nonprolifer-
ating Cells in Ptenpc/ Tumors
(A) Western blot analysis and quantification (n = 4)
showing activation of the Jak2/Stat3 pathway in
Ptenpc/ tumors.
(B) H&E and pStat3(Y705) staining in AP lobes of
Ptenpc+/+ and Ptenpc/ at 12 weeks of age.
(C) Confocal immunofluorescence (IF) images on
Ptenpc+/+ and Ptenpc/ paraffin-embedded APs
tumor sections (n = 3) in blue nuclear marker
(DAPI) and in green pStat3(Y705)-positive cells.
(D) Quantification of (B) and (C); bars represent the
percentage of pStat3(Y705)-positive cells.
(E) Confocal IF images on Ptenpc+/+ and Ptenpc/
paraffin-embedded APs tumor sections. Nuclear
marker DAPI (blue), proliferation marker Ki67 (red),
pStat3(Y705) (green), and prostate marker CK18
(gray; n = 3).
(F) Quantification of (E), bars represent the per-
centage of pStat3(Y705) single-positive, Ki-67
single-positive, and pStat3(Y705) /Ki-67 double-
positive cells (n = total number of cells counted on
three different tumors). Data are represented as
mean ± SEM (**p < 0.01; ***p < 0.001).
tive for the proliferation marker Ki-67
and positive for the senescence marker
pHP1g (Figures 2E, 2F, S2C, and S2D).
Altogether, our data suggest that, at least
in Ptenpc/ tumors, Stat3 is mainly acti-
vated in nonproliferating senescent cells,
in agreement with recent evidence in a
different mouse model (Jackson et al.,
2012).
In Ptenpc/; Stat3pc/ Senescent
Tumors, the Antitumor Immune
Response Is Reactivated
To study the role of Stat3 in PICS and
specifically its contribution to the SASP,
we crossed PtenloxP/loxP; Pb-Cre4 mice
with the Stat3loxP/loxP mice (Akira, 2000)
to generate the PtenloxP/loxP; Stat3loxP/loxP
Pb-Cre4mouse model (hereafter referred
to as Ptenpc/; Stat3pc/). We first confirmed prostate-specific
deletion of both Pten and Stat3 in the mouse prostate epithelium
(Figure S3A). Next, we looked for the presence of senescence in
the Ptenpc/; Stat3pc/ tumors and found upregulation of both
p53 protein levels and SA-b-gal-staining positivity, indicating
that Stat3 was not needed for the execution and maintenance
of PICS (Figures 3A and 3B). Next, we checked the status of
NF-kB, whose function controls both cell-autonomous and
non-cell-autonomous aspects of senescence (Chien et al.,
2011), and found that NF-kB was activated to a similar extent
in both Ptenpc/ and Ptenpc/; Stat3pc/ tumors (Figure 3A).
Importantly, Stat3 inactivation in both normal and Pten-null pros-
tate epithelium did not affect cell proliferation and apoptosis (Fig-
ures S3B and S3C). However, the SASP of Ptenpc/; Stat3pc/
tumors had reduced levels of the immune-suppressive
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chemokines (CXCL2, granulocyte colony-stimulating factor,
granulocyte macrophage colony-stimulating factor [GM-CSF],
macrophage colony-stimulating factor [M-CSF], C5a, IL10, and
IL13), whereas retained high levels of potent chemoattractants
for B and T cells such as B lymphocyte chemoattractant, mono-
cyte chemoattractant protein-1 (MCP-1), and CXCL10 when
compared to the SASP of Ptenpc/ tumors (Figure 3C; Ansel
et al., 2002; Deshmane et al., 2009; Dufour et al., 2002). Taken
together, these data demonstrate that inactivation of Stat3 in
Pten-null tumors reprograms the SASP of PICS (hereafter
referred to as R-SASP) without affecting proliferation, apoptosis,
and NF-kB signaling. In line with our findings, Ptenpc/;
Stat3pc/mice developed senescent tumors strongly infiltrated
by immune cells. FACS analysis on the immune cell fraction of
Ptenpc/; Stat3pc/ tumors showed a strong reduction in the
percentage of MDSCs (Figure 3D) and increased infiltration of
CD8+, NK, and B cells (Figures 3E and 3F). Interestingly, the infil-
tration of immune cells in the Ptenpc/; Stat3pc/ mouse pros-
tatic epithelium occurred progressively after Pb-Cre activation,
reaching a maximum at 15 weeks of age (see Figure S3D). More-
over, in Ptenpc/; Stat3pc/ tumors, both CD8+ and NK cells
were cytotoxic, as indicated by the expression of the degranula-
tion marker CD107a (Alter et al., 2004; Figures 3G and S3E), and
B cells were present both as plasma cells (CD19+B220) and an-
tigen-presenting cells (CD19+B220+; Figure S3F). Restoration of
the immune response in Ptenpc/; Stat3pc/ tumors was also
associated with a marked and progressive decrease in p16
mRNA levels (Figure S3G) and a concomitant increase inGranzy-
meB mRNA levels at 15 weeks of age (Figure 3H). These data
suggest that senescent cells were progressively cleared in these
tumors, in agreement with previous data in a different model
(Kang et al., 2011). Notably, whereas at early stage of tumorigen-
esis, Ptenpc/; Stat3pc/ and Ptenpc/ tumors had compara-
ble tumor size, at late stages, Ptenpc/; Stat3pc/ tumors were
smaller in size (roughly 70%; Figures 3I, 3J, and Figure S4A) and
presented a reduced stromal compartment (Figure S4B). Impor-
tantly, whereas the totality (100%) of Ptenpc/ mice developed
invasive prostate cancer at late stage of tumorigenesis
(>15 weeks), only 25% of aged match Ptenpc/; Stat3pc/ tu-
mors developed invasive prostate tumors (Figures 3J and 3K).
All together, our data show that Stat3 inactivation in Pten-defi-
cient tumors promotes an immune response switch (from immu-
nosuppressive to active immunosurveillance) by decreasing the
levels of specific cytokines in the tumor microenvironment, thus
unmasking the immunostimulatory features of the SASP.
Docetaxel Treatment Enhances Senescence but Does
Not Cause Significant Tumor Regression in Pten-Null
Prostate Tumors
We next investigated whether the SASP of PICS could limit the
efficacy of treatments that enhance senescence in Pten-null
tumors. Docetaxel is the gold standard therapy for recurrent
prostate cancer patients that no longer respond to hormonal
approaches and is the only US-Food-and-Drug-Administra-
tion-approved first-line chemotherapy in these patients (Anto-
narakis and Armstrong, 2011). Previous evidence showed that
docetaxel opposes tumor formation by promoting senescence
(Schwarze et al., 2005). We next checked whether docetaxel
treatment could be effective in Ptenpc/ mice by enhancing
senescence. Despite the fact that docetaxel treatment enhanced
senescence in Pten-null tumors as measured by upregulation of
both p16, p21 mRNA levels and immunohistochemistry staining
for p16 (Figures S5A and S5B), it did not trigger a significant
reduction in tumor volume (Figure S5C, bottom). Moreover, we
did not detect significant effect of docetaxel treatment on tumor
histology (Figure S5C, top). Of note, the increase in p16 staining
correlated with strong activation of pStat3 in tumors (Figure S5B,
bottom) and absence of an antitumor immune response as
shownby the low levels ofGranzymeBmRNA levels (Figure S5D).
Moreover, in Ptenpc/ tumors treated with docetaxel, both
CD8+ and the NK cells were not cytotoxic, as indicated by lack
of the degranulation marker CD107a in those cells (data not
shown). In summary, docetaxel treatment increased senescence
but had modest activity in Ptenpc/ tumors. These data are
highly relevant considering the frequent loss of PTEN in prostate
cancer (Trotman et al., 2003). These findings are also in line with
a recent study demonstrating lack of response to docetaxel in
patients with prostate cancers with decreased levels of PTEN
(Antonarakis et al., 2012).
Pharmacological Inhibition of the Jak2/Stat3 Pathway
Leads to an Effective Antitumor Immune Response in
Prostate Tumors Treated with Docetaxel
We next hypothesized that the modest efficacy of docetaxel
in Pten-null tumors was related to the absence of an effective
antitumor immune response. Driven by the genetic evidences
obtained from Ptenpc/; Stat3pc/ mice, we reasoned that
pharmacological inhibition of the Jak2/Stat3 pathway could be
an effective strategy to reprogram the SASP and restore an anti-
tumor immune response in docetaxel-treated, Pten-deficient
tumors. We tested this hypothesis in a preclinical trial by
combining the JAK2 inhibitor NVP-BSK805 (Baffert et al., 2010;
Marotta et al., 2011) with docetaxel in a cohort of Ptenpc/
mice (Figure 4A). In this respect, whereas docetaxel and
NVP-BSK805 alone displayed a modest single-agent antitumor
response, the combination of docetaxel and NVP-NSK805 led
to a profound reduction in tumor size with near complete patho-
logical responses and no evidence of tumor invasion (Figures 4B
and 4C). As observed in Ptenpc/; Stat3pc/ tumors, inhibition
of the Jak2/Stat3 pathway reprogrammed the SASP in doce-
taxel-treated mice (Figure 4D), favoring an active immune
response, as indicated by the strong infiltration of CD3+ T cells
and increased mRNA levels of the cytotoxic marker GranzymeB
(Figures 4E and 4F). Of note, the increased intratumor levels of
GranzymeB in mice treated with docetaxel+NVP-BSK805 were
associated with an increased percentage of apoptotic cells, in
agreement with the proapoptotic function of GranzymeB (Tra-
pani and Sutton, 2003; Figure 4G). At 12 weeks of age, both do-
cetaxel- and docetaxel+NVP-BSK805-treated tumors exhibited
a strong senescence response, as indicated by SA-b-gal positiv-
ity (Figure 4H). However, only in mice treated with docetaxel+
NVP-BSK805, senescent cells were surrounded by T cells (Fig-
ure 4H). As a consequence, the percentage of senescent cells
was strongly reduced in mice treated with NVP-BSK805 alone
or in combination with docetaxel (Figure 4I). These data demon-
strate that treatments targeting the Jak/Stat3 pathway may be
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Figure 3. SASP Reprogramming Promotes an Antitumor Immune Response in Ptenpc/; Stat3/ Mice
(A) Western blot showing the status of p53 and pIKBa in Ptenpc+/+, Ptenpc/, and Ptenpc/; Stat3/ prostate tumors. DKO, double knockout.
(B) Representative images of SA-b-gal (bottom) and H&E (top) staining ofPtenpc/ andPtenpc/;Stat3/ tumors at 15weeks. Images aremagnified3 20. Inset
shows infiltrated immune cells.
(C) Quantification of the cytokine protein profile of purified prostatic epithelial cell isolated from Ptenpc+/+, Ptenpc/, and Ptenpc/; Stat3/ prostates (n = 3).
(legend continued on next page)
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successfully used alone, or in combination with prosenescence
compounds, to reprogram the SASP and promote an antitumor
immune response in Pten-deficient tumors.
The Difference between the SASP of PICS and OIS
Depends on the Genetic Background of the Senescent
Tumor Cells
Previous findings demonstrate that the SASP of NrasG12V-
driven senescent tumors trigger senescence surveillance and
tumor clearance (Kang et al., 2011). However, the SASP of
PICS lacks this capability. We reasoned that the difference in
the genetic background of senescent tumor cells could explain
this phenomenon. To validate this hypothesis, we used the
KrasLSL-G12D/+; PbCre prostate conditional mouse model (here-
after referred as to PbKras (G12D)) to compare the effects of
the SASP of PICS and OIS in vivo (Tuveson et al., 2004). In
agreement with previous findings, PbKras(G12D) mice devel-
oped hyperplasia/low-grade PIN in absence of invasive pros-
tate cancer, even at late stage of disease (Figure 5A; Pearson
et al., 2009). Notably, PbKras (G12D) prostate lesions from 14-
week-old mice were senescent, as demonstrated by increased
b-galactosidase staining and p16 mRNA levels (Figures 5A and
5B). Next, we compared the SASP of PICS and OIS by
analyzing prostate epithelial cells at the onset of senescence.
Surprisingly, the immunosuppressive cytokines upregulated
in PICS were only slightly increased in the secretome of
OIS. Indeed, PbKras(G12D) tumors were characterized by lower
levels of CXCL-2 and IL10 (Figure 5C). Moreover, in stark
contrast to PICS, immunohistochemical analysis in
PbKras(G12D) senescent tumors showed low level of Stat3
phosphorylation (Figure 5D). Immunophenotyping of
PbKras(G12D) tumors revealed that CD11b+Gr1+ cells were
almost undetectable when compared with the Ptenpc/ tu-
mors (Figure 5E). Moreover, we found an increased percentage
of interferon-g releasing CD8+-positive cells in PbKras(G12D)
tumors (Figure 5F). Immune-mediated cytotoxic activity,
measured by GranyzmeB mRNA levels, was also increased in
these prostate lesions (Figure 5G). Importantly, in PbKras(G12D)
tumor, senescent cells were progressively removed from the
tumor, as indicated by the decay of SA-b-gal staining over
time (Figure 5H), in agreement with previous findings in a
different model of OIS (Kang et al., 2011). In summary, these
findings suggest that activation of the Jak2/Stat3 pathway is
the key determinant for the different SASPs and senescence-
associated immune responses between PICS and OIS. Our
data also suggest that compounds that target the JAK2/
STAT3 pathway could be more effectively used in PTEN-null
tumors rather than in tumors driven by activation of the
mitogen-activated protein kinase pathway.
Loss of PTEN Drives Downregulation of PTPN11/SHP2
that Sustains theActivation of the JAK2/STAT3 Pathway
We next sought the mechanism that leads to increased activa-
tion of the Jak2/Stat3 pathway in Pten-null senescent tumors
by focusing on intrinsic regulatory negative systems of this
pathway. Protein tyrosine phosphatase (PTP) SHP2 (also known
as PTPN11) is one of the major negative regulators of the JAK2/
STAT3 pathway. Indeed, hepatocyte-specific deletion of Shp2 in
mouse promotes inflammation and tumorigenesis through the
activation of Stat3 (Bard-Chapeau et al., 2011). Interestingly,
Shp2 mRNA levels were strongly reduced in Ptenpc/ tumors
when compared to PbKras(G12D) tumors and normal prostates
(Figure 6A). Western blot analysis confirmed that the levels of
Shp2 were reduced in Ptenpc/ tumors at the onset of senes-
cence (Figure 6B). To functionally validate these results in human
cancer cell lines, we generated a doxycycline-inducible sh-PTEN
DU-145 prostate stable cell line (DU-145sh-PTEN) (Figure S6A).
DU-145 cells retain 50% of the endogenous level of PTEN. Strik-
ingly, further downregulation of PTEN was accompanied by the
concomitant reduction in both SHP2 protein and mRNA levels
and increased phosphorylation of STAT3 at steady state (Figures
6C and S6A). Similar results were also obtained in DU-145 cells
when PTEN was downregulated by mean of two different small
interfering RNAs (siRNAs) (Figure S6B). Moreover, in a time
course experiment, we found that, when DU-145sh-PTEN cells
were starved and stimulated with recombinant IL-6, phosphory-
lation of STAT3 lasted longer in cells induced with doxycycline
(Figure 6D). Finally, rescue experiments showed that, when
wild-type (WT) SHP2was overexpressed in DU-145 cells in pres-
ence of siPTEN, the levels of pSTAT3were reduced (Figure S6C).
Consistently, PTPN11/SHP2 downregulation by mean of siRNA
in both DU-145 cancer cells and RWPE-1 untransformed cells
led to an increase of pSTAT3 protein levels (Figure S6D). These
data demonstrate that downregulation of PTEN and SHP2
directly sustained JAK2/STAT3 activation. Note that Shp2
mRNA level remained downregulated in Ptenpc/; Stat3pc/
tumors as well, suggesting that Shp2 is not under the transcrip-
tional control of Stat3 (Figure S6E). Broad bioinformatics analysis
conducted on ten different data sets of human prostate cancer
(n = 1,086) confirmed the correlation between PTEN and SHP2
(Figures 6E and S6F). Moreover, patients with low levels of
both PTEN and SHP2 had a worse prognosis when compared
with the other groups (Figure 6F). Lastly, the correlation between
PTEN and SHP2 was also validated in a human prostate cancer
(D) FACS analysis of tumor-infiltrating CD11b+Gr-1+ immune cells in Ptenpc/ and Ptenpc/; Stat3/ (n = 4; *p < 0.05) tumors.
(E) Immunophenotyping of Ptenpc/; Stat3/ tumors (n = 3; *p < 0.05; **p < 0.01).
(F) IF showing tumor-infiltrating CD3+ cells in Ptenpc/ and Ptenpc/; Stat3/ prostate tumors.
(G) Quantification by FACS analysis of CD8+ and NK1.1+ degranulation (n = 3; **p < 0.01).
(H) GranzymeB mRNA levels in Ptenpc/; Stat3/ tumors (n = 3; *p < 0.05).
(I) Relative tumor volume of Ptenpc/ and Ptenpc/; Stat3/ APs at different weeks (each group n = 3–6; ***p < 0.001).
(J) Gross anatomy and H&E staining of representative Ptenpc/ and Ptenpc/; Stat3/ APs from 20- to 25-week-old mice. Images are magnified 3 10. Inset
shows APs from Ptenpc/ and Ptenpc/; Stat3/ at 9 weeks.
(K) Percentage ofmice presenting an invasive phenotype in APs fromPtenpc/ andPtenpc/;Stat3/ tumors at different weeks (each group n = 3; ***p < 0.001).
Data are represented as mean ± SEM.
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tissue microarray (TMA) (Figure 6G). In agreement with our data
in mouse models, we also found a strong anticorrelation be-
tween decreased PTEN and SHP2 levels (PTENlowSHP2low)
and increased JAK2 phosphorylation in human prostate tumors
(Figure 6G). Of note, this anticorrelation appeared even
stronger in prostate cancers with high Gleason score (R7; Fig-
ure 6H). These findings support the emerging view of SHP2 as
potential tumor suppressor also in prostate cancer in line with
recent evidence in other tumor types (Bard-Chapeau et al.,
2011; Chan and Feng, 2007; Yang et al., 2013). Finally, PTEN
and SHP2 correlation was also found in a PANCANCER analysis
including 5,703 tumor samples of different histology such as
breast, melanoma, lung adenocarcinoma, kidney, and clear
cell carcinoma (Figures 7A, S7A, and S7B). As found for prostate
cancer patients, low levels of both PTEN and SHP2 were also
associated with the worst clinical outcome (Figure 7B).
This finding suggests that the correlation between PTEN and
SHP2 levels is a general phenomenon frequently observed in a
variety of tumors at different stages of disease.
DISCUSSION
The mechanisms that link the SASP to tumorigenesis are poorly
understood and remain a subject of intense investigation and
debate. On this line, different studies have reported that the
SASP can exert pro- as well as antitumorigenic effects (Coppe´
et al., 2010; Kang et al., 2011; Xue et al., 2007; Rodier and Cam-
pisi, 2011; Davalos et al., 2010). However, there has been little
investigation into the possibility to reprogram the SASP of a se-
nescent tumor in order to abolish its protumorigenic effects while
retaining its immunostimulatory features. In this study, we pro-
vide evidence that the SASP of senescent tumors can be both
genetically and pharmacologically reprogrammed and that the
efficacy of chemotherapy is enhanced in the context of
R-SASP. Moreover, our findings demonstrate that the SASP of
PICS is orchestrated by both NF-kB and Stat3 activation. Both
genetic and pharmacological inactivation of the Jak2/Stat3
pathway does not abolish the SASP of PICS but drives an overall
reprogramming of the senescence secretome retaining a posi-
tive NF-kB signature (Chien et al., 2011). On this line, the
R-SASP of Pten-null senescent tumors has reduced levels of cy-
tokines, such as CXCL1/CXCL2, GM-CSF, M-CSF, IL10, and
IL13, involved in the recruitment and activation of MDSCs but
retains increased levels of immunostimulatory chemokine such
as MCP-1, previously shown to activate senescence surveil-
lance (Gabrilovich and Nagaraj, 2009; Xue et al., 2007; Zitvogel
et al., 2008). Importantly, we provide evidence that R-SASP im-
proves chemotherapy efficacy in Pten-null tumors. Indeed, do-
cetaxel drives a strong senescence response in Pten-null tumors
but fails to activate an antitumor immune response and tumor
clearance. These findings have immediate implications for the
design of clinical trials evaluating the efficacy of docetaxel or
novel chemotherapies, whose mechanism of action is based
on senescence induction in prostate cancer patients. Our pre-
clinical data predict that single-agent docetaxel will mostly result
in disease stabilization, rather than tumor regression, particularly
in PTEN-null tumors that account for the majority of primary and
metastatic prostate cancers and that often retain an intact
p53 status (Schlomm et al., 2008). A recent clinical trial demon-
strates that PTEN-deficient prostate cancer patients are resis-
tant to docetaxel treatment in line with our findings in the mouse
model (Antonarakis et al., 2012). In this respect, our data suggest
that combined therapy with JAK inhibitors should promote the
reprogramming of the SASP, leading to an antitumor immune
response in docetaxel-treated patients (Figure S7C, model).
In addition, the direct comparison between two different types
of senescence responses in prostate, PICS versus OIS,
provides insights on the mechanisms that lead to the establish-
ment of a protumorigenic SASP in senescent tumors. Indeed,
in PbKras(G12D)-driven senescent tumors (OIS), and in stark
contrast to PICS, we did not observe downregulation of SHP2
and activation of Stat3. Absence of Stat3 activation in OIS was
associated with a distinct SASP compared to PICS, which was
characterized by a lower level of immune-suppressive chemo-
kines and high levels of chemoattractants. This explains the
absence of tumor-infiltrating MDSCs, the strong activation of
T cells, and the progressive decay in the number of senescence
tumor cells in OIS. Because the effects of the SASP have been
recently shown to be spatially restricted, it is possible that the
levels of the immunosuppressive chemokines secreted by OIS
are not sufficient to exert prominent paracrine effects on the
tumor microenvironment (Acosta et al., 2013).
Lack of senescence surveillance in PICS, but not OIS, may
explain at least in part why Pten-null prostate tumors became
invasive at late stage whereas PbKras(G12D) mice develop only
benign tumor lesions. All together, these data suggest that
Figure 4. SASP Reprogramming Enhances Docetaxel Efficacy in Ptenpc/ Tumors
(A) Schedule of treatment used in the preclinical trial with the Jak2 inhibitor NVP-BSK805 and docetaxel in Ptenpc/ mice. Starting from 8 weeks of age, mice
were treated daily for 4 weeks with a dose of 100 mg/kg of NVP-BSK805 alone or in combination with weekly docetaxel at 10 mg/kg (top). Analysis of tumor
volume in the indicated treatment groups (bottom; n = 6–10; *p < 0.05; **p < 0.01).
(B) H&E, pStat3y705, and CD3 staining in Ptenpc/ tumors treated with NVP-BSK805, docetaxel, and docetaxel+NVP-BSK805. pStat3 staining is used as control
to assess inhibition of the Jak2/Stat3 pathway after treatment with NVP-BSK805.
(C) Quantification of PIN-affected glands after the treatments.
(D) Cytokine profile of the reprogrammed SASP (R-SASP) in the indicated treatment groups (n = 5; *p < 0.05; **p < 0.01; mice = 12 weeks of age).
(E) Quantification of the tumor-infiltrating CD3+-positive cells shown in (B) (n = 3; **p < 0.01).
(F)GranzymeBmRNA levels inPtenpc/ tumors treatedwith NVP-BSK805-, docetaxel-, and docetaxel+NVP-BSK805-treated tumors (n = 3; *p < 0.05; **p < 0.01;
***p < 0.001).
(G) Quantification of cleaved-caspase 3-positive cells (n = 3; ***p < 0.001).
(H) IF confocal images showing the localization of CD3+-positive cells (red) in close proximity of senescent cells (green).
(I) Representative IF confocal images showing the percentage of pHP1g-positive senescent cells (green) in Ptenpc/-treated mice. Data are represented as
mean ± SEM.
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Figure 5. Comparative Analysis of PICS versus OIS in Prostates
(A) H&E (top) and b-galactosidase staining (bottom) of Ptenpc+/+, Pten/, and Kras(G12D) prostates at 14 weeks of age.
(B) p16 mRNA levels in Ptenpc+/+, Ptenpc/ (PICS), and Kras(G12D) (OIS) prostates.
(C) Different SASP intensity between PICS and OIS (n = 3; *p < 0.05; **p < 0.01).
(D) pStat3Y705 staining (left) and its quantification (right) on paraffin sections from Ptenpc+/+, Ptenpc/ (PICS), and Kras(G12D) (OIS) prostates (n = 3).
(E) FACS analysis (and quantification of CD11b+GR1+ cells in Ptenpc+/+, Ptenpc/ [PICS], and Kras(G12D) [OIS] prostates). Percentages calculated on CD45+-
gated cells.
(F) Percentage of interferon-g-releasing CD8+ cells (gated on CD45+ cells) in Ptenpc+/+, Ptenpc/ (PICS), and Kras(G12D) (OIS) prostates (n = 3).
(G) GranzymeB mRNA levels in Ptenpc/ (PICS), Ptenpc/; Stat3pc/ (PICS), and Kras(G12D) (OIS) senescent prostate tumors (n = 3).
(H) Representative images showing the decay of SA-b-galactosidase staining over time (14, 20, and 24 weeks) in Kras(G12D) tumors.
Data are represented as mean ± SEM.
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Figure 6. Correlation between PTEN and PTPN11/SHP2 Levels in Both Mouse and Human Prostate Cancers
(A) Shp2 mRNA levels in Ptenpc+/+, Ptenpc/ (PICS), and in Kras(G12D) (OIS) tumors (n = 3; **p < 0.01).
(B) Western blot analysis showing the reduced Shp2 protein levels in Ptenpc+/+ and Ptenpc/ purified epithelial prostate cells at the onset of senescence (8 weeks
Ptenpc/ tumors; high-grade PIN and 14 weeks Kras(G12D); low-grade PIN).
(C) Western blot analysis and quantification of PTEN, SHP2, and STAT3 levels in DU-145 human prostate tumor cells infected with an inducible small hairpin RNA
for PTEN.
(legend continued on next page)
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activation of Jak2/Stat3 pathway is the key determinant underly-
ing the difference between the SASPs of PICS and OIS and
demonstrate that the protumorigenic features of the SASP
depend on the genetic background of senescent tumor cells.
Our findings establish a direct correlation between the levels of
PTEN and SHP2 in both mouse and human tumors. Recent
studies have demonstrated that loss of SHP2 activity or deletion
of Ptpn11, the gene encoding for SHP2, promote tumorigenesis
in different mouse models by sustaining the activation of the
JAK/STAT3 pathway (Bard-Chapeau et al., 2011; Zhu et al.,
2013; Yang et al., 2013). Our PANCANCER analysis also demon-
strated that the correlation between the levels of PTEN and
SHP2 exist in different types of human tumors in addition to pros-
tate cancer. Finally, patient stratification based on the levels of
PTEN and SHP2 showed that tumors with low levels of both
PTEN and SHP2 had the worst prognosis, reinforcing the poten-
tial clinical implication of our findings also in a broader scenario
beyond the context of senescence tumor lesions.
EXPERIMENTAL PROCEDURES
Mice
PtenloxP/loxP mice were generated and genotyped as previously described (Ali-
monti et al., 2010; Chen et al., 2005; Trotman et al., 2003). Stat3loxP/loxP
mice were generated and provided by Oriental BioService. Rag1/ mice
were a kind gift from Prof. Fabio Grassi. Female PtenloxP/loxP; Stat3loxP/loxP and
PtenloxP/loxP; Rag1/ mice were crossed with male PB-Cre4 transgenic mice
and genotyped. For Stat3, Stat3loxP/loxP primer 1 (50-CCTGAAGACCAAGTTCAT
CTGTGTGAC-30) and primer 2 (50-CACACAAGCCATCAAACTCTGGTCTCC-30)
were used. For Rag1/ primer 1 (50-GAGGTTCCGCTACGACTCTG 30) and
primer 2 (50-CCGGACAAGTTTTTCATCGT-30) primer 3 (Neo; 50-TGGATGTG
GAATGTGTGCGAG-30) were used. All mice were maintained under specific
pathogen-free conditions in the animal facilities of the Institute for Research in
Biomedicine, and experiments were performed according to state guidelines
and approved by the local ethics committee.
Western Blot, Immunohistochemistry, and Immunofluorescence
Tissue and purified epithelial lysates were prepared with RIPA buffer (13 PBS,
1% Nonidet P40, 0.5% sodium deoxycholate, 0.1% SDS, and protease inhib-
itor cocktail [Roche]). The following antibodies were used for western blotting:
rabbit polyclonal anti-Pten (9552; Cell Signaling Technology), rabbit mono-
clonal anti-phospho Stat3 Tyr705 (D3A7; CST), mouse monoclonal Stat3
(124H6; CST), rabbit monoclonal anti-Jak2 (D2E12; CST), rabbit polyclonal
anti-phospho- Jak2 (3771; CST), rabbit polyclonal anti-Akt and anti-phospho-
serine 473 of Akt (CST), rabbit polyclonal anti-p16 (M156; Santa Cruz Biotech-
nology), mouse monoclonal anti-b-actin (AC-74; Sigma), rabbit monoclonal
anti-SHP-1 (C14H6; CST), and rabbit monoclonal anti-SHP-2 (D50F2; CST).
For IHC, tissues were fixed in 10% formalin and embedded in paraffin in
accordance with standard procedures. Sections were stained for phospho
Stat3 Tyr705(D3A7; CST), Stat3 (124H6; CST), Pten (51-2400; Invitrogen),
Ki67(Clone SP6; Lab Vision), anti-CD3 (Dako), and anti-CD45R/B220 (BD
Pharmigen). For IF on tissue, paraffin-embedded sections were stained for
rabbit monoclonal anti-phospho Stat3 Tyr705 (D3A7; CST) and mouse mono-
clonal anti-a-tubulin (DM1A; CST). Confocal sections were obtained with Leica
TCS SP5 confocal microscope.
Prostatic Epithelial Cell Purification and Cytokine Array
Ptenpc+/+; Stat3pc+/+; Ptenpc+/+, Ptenpc/, and Ptenpc/; Stat3pc/ 9-week-
old mice were scarified, and whole prostates (n = 3 per group) were isolated
and processed to single-cell suspension (Lukacs et al., 2010) for MACS. Single
cells were stained with fluorescein isothiocyanate (FITC)-anti-CD34 (stroma),
FITC-anti-Ter119 (erythrocytes), FITC-anti-CD31 (endothelial), and FITC-
anti-CD45 (leukocytes) and incubated 20 min on ice. All antibodies (BD Biosci-
ences) were used at 1:300; cells were then loaded into MS column (Miltenyi
Biotec) for MACS separation, and unstained epithelial cells were collected in
the negative fraction. Purified prostatic epithelial cells were processed as indi-
cated in cytokine array kit (R&D Systems). Developed films were scanned, ob-
tained images were analyzed using ImageJ 1.43u, and background signals
were subtracted from the experimental values.
Autopsy and Histopathology
Animals were autopsied, and all tissues were examined regardless of their
pathological status. Normal and tumor tissue samples were fixed in 10%
neutral-buffered formalin (Sigma) overnight. Tissues were processed by
(D) Time course experiment showing the sustained phosphorylation of STAT3 upon PTEN downregulation in DU-145 prostate cells. Cells were starved for 12 hr in
presence of 0.5% of FCS and then stimulated with IL-6 (40 ng/ml) and STAT3 phosphorylation assessed by western blot at the indicated time points.
(E) Heatmaps and scattered plot showing the correlation between PTEN and SHP2 mRNA levels in a human data set of normal prostates and prostate tumors
(GSE21034).
(F) Kaplan-Meier survival curves of three different human prostate cancer data sets. The blue curve represents patients with low levels of both PTEN and SHP2;
the red curve represents patients with high levels of both PTEN and SHP2.
(G) IHC for PTEN, SHP2/PTPN11, and pJAK2 on a tissue microarray (TMA) of human prostate cancer.
(H) Table showing the correlation between PTEN and SHP2/PTPN11 protein levels and the anticorrelation between the protein levels of PTEN-SHP2/PTPN11 and
pJAK2; analysis performed on the TMA in (G). Data are represented as mean ± SEM. Images are magnified 3 20.
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Figure 7. The Correlation between PTEN
and PTPN11/SHP2 Is Frequently Found in
Cancer
(A) Heatmap showing the correlation between
PTEN and PTPN11/SHP2 in a PANCACER anal-
ysis performed on 25 different tumor types (5,703
samples).
(B) Overall survival showing the poor clinical
outcome of patients with low levels of both PTEN
and PTPN11/SHP2 (red line) when compared with
the group of patients with high levels of both PTEN
and PTPN11/SHP2 (blue line); the group of pa-
tients with low levels of both PTEN and PTPN11/
SHP2 are the patients highlighted in the red box of
the heatmap of (A).
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ethanol dehydration and embedded in paraffin according to standard proto-
cols. Sections (5 mm) were prepared for antibody detection and hematoxylin
and eosin (H&E) staining. To evaluate evidence of invasion, sections were
cut at 20 mm intervals and H&E stained. Slides were prepared containing three
to five of these interval sections.
Flow Cytometry Analysis of Cell Phenotype
Samples were acquired on a BD FACSCanto II flow cytometer (BD Biosci-
ences) after fixation with 1% formaldehyde (Sigma-Aldrich). Cells resus-
pended in PBS containing 1% fetal calf serum (FCS) (Sigma-Aldrich) were
stained for 10 min at room temperature with the following anti-mouse
monoclonal antibodies: CD45 eFluor 450 (clone 30-F11); CD3e FITC (clone
145-2C11); CD4 allophycocyanin (APC)-eFluor 780 (clone GK1.5); CD8 phyco-
erythrin (PE) (clone 53-6.7); CD25 PE-Cy7 (clone PC61.5); NK1.1 eFluor 450
(clone PK136); lysosomal-associated membrane protein 1 (CD107a) APC
(clone 1D4B); Ly-6G (Gr-1) PE (clone RB6-8C5); CD11b APC (clone M1/70);
CD19 FITC (clone 6D5); and CD45R/B220 FITC (clone RA3-6B2). All the anti-
bodies were purchased from eBioscience. GR1+CD11b+ were sorted from the
prostate single-cell suspension using a FACSAria cell sorter (BD Biosciences)
after staining with anti-CD45, anti-GR1, and anti-CD11b antibodies for 30 min
at 4C in PBS containing 1% FCS. CD8+ T cells were sorted based on the
expression of CD45, CD3, and CD8. Data were analyzed using FlowJo soft-
ware (TreeStar).
In Vitro Suppression Assay
In vitro suppression assays were carried out in RPMI/10% FCS in 96-well U-
bottom plates (Corning) with 2.5 3 104 CD8+ splenocytes as responder cells
and titrated amounts of FACS-sorted GR1+CD11b+ or CD3+CD4+CD25+
Treg used as a positive control. CD8+ T cells were labeled with 5 mM CFSE
(Molecular Probes), and stimulation was carried out with plate-bound anti-
CD3 (3C11; 2 mg/ml) and anti-CD28 (2 mg/ml; BD PharMingen). After 4 days
at 37C, proliferation of CD8+ T cells was analyzed by FACSCanto flow
cytometer.
RNA Expression Analysis
RNA isolation (QIAGEN) and TaqMan reverse transcriptase reaction (Applied
Biosystems) were according to the manufacturer’s instructions. Quantitative
PCR reactions (Bio-Rad) for each sample were done in triplicate. Sequences
used for PAI-1, IL6, MCP-1, CXCL1, CXCL2, GM-CSF, M-CSF, IL10,
ICAM-1, SHP2, PTEN, p21, p16, and GranzymeB were as follows: PAI-1 for-
ward 50-TTGAATCCCATAGCTGCTT-30, reverse 50-GACACGCCATAGGGA
GAGA-30; IL6 forward 50-TAGTCCTTCCTACCCCAATTT-30, reverse 50-TTGG
TCCTTAGCCACTCCTTC-30; MCP-1 forward 50-GTGGGGCGTTAAACTG
CAT-30, reverse 50-CAGGTCCCTGTCATGCTTCT-30; CXCL1 forward 50-CTG
GGATTCACCTCAAGAACATC-30, reverse 50-CAGGGTCAAGGCAAGCCTC-
30; CXCL2 forward 50-CCAACCACCAGGCTACAGG-30, reverse 50-GCGTCA
CACTCAAGCTCTG-30; GM-CSF forward 50-GGCCTTGGAAGCATGTAGA
GG-30, reverse 50-GGAGAACTCGTTAGAGACGACTT-30; M-CSF forward 50-
TGCTAGGGGTGGCTTTAGG-30, reverse 50-CAACAGCTTTGCTAAGTGCT
CTA-30; IL-10 forward 50-GCTCTTACTGACTGGCATGAG-30, reverse 50-
CGCAGCTCTAGGAGCATGTG-30; ICAM-1 forward 50-GTGATGCTCAGGTAT
CCATCCA-30, reverse 50-CACAGTTCTCAAAGCACAGCG-30; SHP2 forward
50-GAACTGTGCAGATCCTACCTCT-30, reverse 50-TCTGGCTCTCTCGTACA
AGAAA-30; PTEN forward 50-TGGATTCGACTTAGACTTGACCT-30, reverse
50-GGTGGGTTATGGTCTTCAAAAGG-30; p21 forward 50-CCCCCAATCGCAA
GGATTCTT-30, reverse 50-CTTGGTTCGGTGGGTCTGTC-30; p16 forward 50-
CGCAGGTTCTTGGTCACTGT-30, reverse 50-TGTTCACGAAAGCCAGAGCG-
30; and GranzymeB forward 50-CCACTCTCGACCCTACATGG-30, reverse 50-
GGCCCCCAAAGTGACATTTATT-30.
Small Hairpin RNA, siRNA, and Plasmids
DU145 prostate cancer cell lines were plated into 6-well dishes and infected
with a doxycycline-inducible pTRIPZ shPTEN (clone id: V2THS_92317; Open
Biosystems; mature sense: 50 GGCGCTATGTGTATTATTA 30). siPTEN_1
(Life Technologies; cat. no. 4392420); siPTEN_2 and siPTPN11 (Thermo Scien-
tific). Plasmid used for the rescue experiments: CMV566 empty vector and
pCMV-SHP2 WT (Addgene).
Gene Expression Profiling
Prostate cancer genome-wide gene expression data sets and clinical infor-
mation were downloaded from Gene Expression Omnibus database or ob-
tained from authors upon request (Glinsky et al., 2004; Setlur et al., 2008;
Taylor et al., 2010). Pancancer data set matrix and clinical information
was downloaded from University of California, Santa Cruz Cancer Genomics
Browser (https://genome-cancer.ucsc.edu). Human cancer cell lines expres-
sion data set and sensitivity values to docetaxel treatment (IC50 values) were
downloaded from http://www.cancerrxgene.org/downloads (Garnett et al.,
2012).
Correlation Analysis
Correlation between gene-expression-derived values in the principle-compo-
nent analysis (PCA) and Pancancer data sets was done using Pearson corre-
lation test, which estimates a correlation value ‘‘r’’ and a significance p value
(r > 0 < 1, direct correlation; r < 0 > 1, inverse correlation). Correlation was
also performed in TMA staining evaluation using the estimated percentage
of positively stained cells as determined by a pathologist (M.S.).
Survival Curves
Differential survival between patient subgroups was plotted and calculated
using Kaplan-Meier curves. Patients were stratified based on PTEN and
PTPN11 score values. In brief, scores were rank ordered and divided in
seven percentiles (from lowest to highest values). We considered samples
having PTEN/PTPN11 low values as those in the first percentile. Such strat-
ification gave significant differences in overall survival within the Pancancer
study (log rank test) and in the high Gleason patients within the PCA data
sets.
Statistical Analysis
Data analysis was performed using a two-tailed unpaired Student’s t test.
Values are expressed as mean ± SEM (*p < 0.05; **p < 0.01; ***p < 0.001).
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SUPPLEMENTAL FIGURE LEGENDS 
Supplementary Figure S1, related to Figure 1. Efficiency of prostatic epithelial purification and 
immunophenotyping of Ptenpc-/- senescent tumors (A) β-galactosidase activity (Fluorescein Di-β-D-
galactopyranoside (FDG) positivity detected by FACS analysis) and mRNA levels of the senescence markers 
p16 (p=0.004), p21 (p=0.01) and PAI-1 (p=0.008) (n=4; **p<0.01). (B) Efficiency of purification obtained 
by magnetic cell sorting (MACS). Immune cells (CD45) , endothelial (CD31) and stromal (CD34) cells were 
stained in FITC and unstained epithelial cells were collected in the negative fraction with a purity >95%. (C) 
Cytokine array profiles in Ptenpc+/+ and Ptenpc-/- prostates (n=3); colored squares indicates individual 
cytokines spotted in duplicate. (D and E) Strategy of gating used for the immunophenotyping of Ptenpc-/- 
senescent tumors. Briefly, the immune cellular fraction in the tumor single cell suspension was identified by 
CD45 staining (pan- leukocyte marker) and different subpopulations were characterized as follow: (D) CD4 
and CD8 staining (T cell), B220 (B cells)  Nk1.1 staining (NK cells). (E) CD11b+Gr1+ (MDSCs) subsets. 
Myeloid cells are marked in the circle. Monocytic  MDSCs (CD11bhiGr1int; left square) and granulocytic 
(CD11bhiGr1hi ; right square) . (F and G) Degranulation of NK and CD8 cells was assessed by staining for 
the degranulation marker CD107a. (H) Ptenpc-/-; Rag1-/- mice lack B and T cells. SSC-A/FSC-A and 
CD3/B220 plots showing the genetic depletion of T and B cells in Ptenpc-/-; Rag1-/- mice. Spleen from a 
Ptenpc-/- was used as a control. Data are represented as mean ± SEM.   
Supplementary Figure S2, related to Figure 2.  Stat3 activation in Ptenpc+/+, Ptenpc+/- and Ptenpc-/- tumors 
(A) H&E (upper panels) and pStat3(Y705) staining (lower panels) of Ptenpc+/+, Ptenpc+/- and Ptenpc-/- anterior 
prostates (APs). (B) Western blot analysis showing Stat3 phosphorylation in Ptenpc+/+, Ptenpc+/- and Ptenpc-/- 
APs. (C) Stat3 is activated in non proliferating cells in Ptenpc-/- tumors. Confocal immunofluorescence 
images (IF) on Ptenpc+/+ and Ptenpc-/- paraffin embedded APs tumor sections; in blue nuclear marker (DAPI), 
in red the proliferation marker (Ki67) and in green pStat3(Y705) positive cells. (D) Confocal 
immunofluorescence images (IF) on Ptenpc+/+ and Ptenpc-/- paraffin embedded APs tumor sections; in blue 
nuclear marker (DAPI), in red the pHP1γ and in green pStat3(Y705) positive cells. Arrows indicate double 
positive cells. Data are represented as mean ± SEM.     
Supplementary Figure S3,  related to Figure 3.  Phenotypic characterization of Ptenpc-/-; Stat3pc-/- 
tumors (A) Immunohistochemical analysis of Pten expression levels showed efficient deletion of Pten in 
both Ptenpc-/- and Ptenpc-/-;Stat3pc-/- prostate tissues. Notably, immunohistochemical analysis shows enhanced 
expression of Stat3 in Ptenpc-/- and efficient loss of Stat3 expression in Ptenpc-/-; Stat3pc-/- mouse models. (B) 
Bars represent the percentage of Ki-67 positive cells in  APs of Ptenpc+/+ ; Stat3pc+/+ , Ptenpc+/+ ; Stat3pc-/- , 
Ptenpc-/- ; Stat3pc+/+  and Ptenpc-/- ; Stat3pc-/- 10 weeks old mice (n=3). (C) IHC showing absence of cleaved-
caspase-3 staining in both Ptenpc-/- ; Stat3pc+/+  and Ptenpc-/- ; Stat3pc-/- APs from 10 weeks old mice (n=3). (D) 
Progressive infiltration of immune cells in Ptenpc-/-; Stat3pc-/- tumors at different time points. (E) Histogram 
showing degranulation of NK cells in Ptenpc-/-; Stat3pc-/- tumors. (F) Representative images from Ptenpc-/-  and 
Ptenpc-/-; Stat3pc-/- sections stained for the B cell marker, B220 (400X) (upper panel) and FACS analysis 
revealing an enrichment of plasma cells  (CD19+ B220-)  in  Ptenpc-/-; Stat3pc-/- tumors when compared to the 
normal levels present in spleen (lower panel). (G) p16 mRNA decay measured at different time points in 
tumors of different genotypes. 
Supplementary Figure S4,  related to Figure 3.  Phenotypic characterization of Ptenpc-/-; Stat3pc-/- 
tumors at late stage (A) Representative images and size of APs from 25 weeks old mice (n=4, **p<0.01). 
(B) H&E staining showing the reduced stroma in Ptenpc-/- ; Stat3pc-/- tumors of 25 weeks old mice. 
Supplementary Figure S5, related to Figure 4.   Docetaxel is poorly effective in Ptenpc-/- tumors  (A) p16 
and p21 mRNA levels in Ptenpc-/- tumors untreated and treated with Docetaxel. (B) (Upper panel) p16 
staining in Ptenpc-/- tumors untreated and treated with Docetaxel. (Lower panel) Quantification of p16 and 
pStat3(Y705) in tumor untreated and treated with Docetaxel (n=3; **p<0.01). (C) H&E staining (upper panel) 
and tumor volume (n=3; **p<0.01) (lower panel)  of Ptenpc-/-  tumors  untreated and treated with Docetaxel.  
(D) GranzymeB mRNA levels in Ptenpc-/- tumors treated with vehicle and  Docetaxel (ns= not significant). 
Data are represented as mean ± SEM.   
Supplementary Figure S6, related to Figure 6.  Correlation between  PTEN/PTPN11 levels in mouse 
and human PCA (A) DU-145 prostate cells stably infected with a Doxycycline (Dox) RFP-labeled 
inducible ShRNA designed against PTEN (upper panel). mRNA levels of PTEN and SHP2 in DU-145shPTEN 
prostate cell line after Dox treatment (lower panel). (B) DU-145 cells transfected with two different siPTEN 
for 72hrs. (C) DU-145 cells co-transfected with an siPTEN and a plasmid expressing wt-SHP2 for 72hrs (D) 
DU-145 and RWPE-1 cell lines transfected with siPTPN11 for 72hrs. (E) Shp2 mRNA levels in Ptenpc-/- ; 
Stat3pc-/- mice. (F) Gene expression levels for PTEN and PTPN11 was analyzed using pearson correlation test 
(see material and methods) in 10 human prostate cancer datasets. Upper bar plots indicate pearson “r” 
correlation values. Bottom bar plots indicates significance of pearson correlations as –log10(p-val) values. 
Blue line corresponds to p-val=0.05, meaning that bars spanning above the line are significant. All 10 
datasets display significant co-expression between PTEN and PTPN11. Numbers on top of the bars indicate a 
specific dataset, listed in the table (bottom right). 
Supplementary Figure S7, related to Figure 7.  PTEN-PTPN11 correlation in PANCANCER analysis 
and model (A) Table shows r values and p-values, per type of sample and cancer cohort (green= PTEN-
PTPN11 correlation is significant ; red= PTEN-PTPN11 correlation is NOT significant). (B) Tumor cohorts 
with significant correlations are shown. Upper bar plots indicate pearson “r” correlation values. Bottom bar 
plots indicate significance of pearson correlations as –log10(p-val) values. Blue line corresponds to p-
val=0.05, meaning that bars spanning above the line are significant (p-val<0.05). Numbers on top of the bars 
indicate a specific dataset, listed in the table. Prostate cancer is highlighted  in yellow. Importantly, all 
significant associations are positive (r >0). (C) Model. PICS is characterized by an immunosuppressive 
SASP shaped by the activation of both Nf-kB and STAT3. Loss of PTEN induces down-regulation of SHP2 
a negative regulator of the JAK2/STAT3 pathway. Our genetic evidence revealed that STAT3 orchestrates 
the immunosuppressive feature of the SASP  by tilting the balance between pro- and anti-tumorigenic 
cytokines in the tumor microenvironment in favor of the pro-tumorigenic cytokines (left panel). Treatment of 
PTEN null tumors with Docetaxel boosts the senescence response but fails to induce an anti-tumor immune 
response. However, when PTEN null tumors are treated with Docetaxel in combination with a JAK2 
inhibitor the SASP is reprogrammed (R-SASP) and the level of pro-tumorigenic cytokines are reduced 
favoring anti-tumor immune response (right panel).   
 
 
 
